These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25426865)

  • 1. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
    Patel U; Cornelius L; Anadkat MJ
    JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
    Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
    Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
    Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
    Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobimetinib (Cotellic) for metastatic melanoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe gastrointestinal toxicity of MEK inhibitors.
    Mourad N; Lourenço N; Delyon J; Eftekhari P; Bertheau P; Allayous C; Ballon A; Pagès C; Allez M; Lebbé C; Baroudjian B;
    Melanoma Res; 2019 Oct; 29(5):556-559. PubMed ID: 31095035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy.
    Pacaud A; Amintas S; Boussemart L; Cappellen D; Gérard E
    Eur J Cancer; 2021 Apr; 147():161-163. PubMed ID: 33684875
    [No Abstract]   [Full Text] [Related]  

  • 9. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
    Adelmann CH; Truong KA; Liang RJ; Bansal V; Gandee L; Saporito RC; Lee W; Du L; Nicholas C; Napoli M; Mino B; South AP; Proby CM; Leigh IM; Coarfa C; Flores ER; Tsai KY
    J Invest Dermatol; 2016 Sep; 136(9):1920-1924. PubMed ID: 27293029
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma.
    Kleemann J; Hrgovic I; Hempel K; Kaufmann R; Meissner M
    Clin Exp Dermatol; 2018 Mar; 43(2):195-196. PubMed ID: 29023842
    [No Abstract]   [Full Text] [Related]  

  • 13. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes.
    Lulli D; Carbone ML; Pastore S
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.
    Fujimura T; Kambayashi Y; Hidaka T; Tamabuchi E; Otake E; Tono H; Mizuashi M; Furudate S; Aiba S
    J Dermatol; 2018 Feb; 45(2):e35-e36. PubMed ID: 28983948
    [No Abstract]   [Full Text] [Related]  

  • 16. Cobimetinib (GDC-0973, XL518).
    Andrlová H; Zeiser R; Meiss F
    Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
    Hussar DA; Kaminski JL
    J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
    [No Abstract]   [Full Text] [Related]  

  • 19. [Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors].
    Rohmer E; Scrivener JN; Schissler C; Cribier B; Lenormand C
    Ann Dermatol Venereol; 2019 Nov; 146(11):725-729. PubMed ID: 31627930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.